Retrieval of Life Affirming Values and their Incorporation into a Suicidality Prevention Plan

Abstract. This article is intended primarily as a companion piece to provide additional background and illustration for a submission by the same authors to The Journal of the American Academy of Child and Adolescent Psychiatry. It is also the second in a series appearing in Conscience Works to characterize recently employed techniques to render psychiatric treatment of children and adolescents in a conscience sensitive manner. It consists of a progressive Case Presentation interwoven with Discussion points, which together demonstrate the retrieval of life affirming values in the context of suicidality management and the incorporation of these values in an overall suicidality prevention plan

Modelo de dirección integral de proyectos para la compañía ypfb chaco s.a. del upstream de la industria de petróleo y gas, en base a la legislación nacional, mejores prácticas y estándares internacionales

The study deals with proposing a comprehensive project management model for the company YPFB Chaco S.A. from the upstream of the oil and gas industry in order to obtain best practices while complying with international standards. The purpose of the study is the integral management of projects of the oil and gas operating companies in the country, taking as a case study the oil company YPFB Chaco S.A. Having as a field of action: the Bolivian economy, human resources, YPFB operations and the Directorate of hydrocarbon projects. The project is proposed due to the decrease in oil production and reserves in the Plurinational State of Bolivia.El estudio trata sobre la proponer un modelo de dirección integral de proyectos para la compañía YPFB Chaco S.A. del upstream de la industria de petróleo y gas con el fin de obtener mejores prácticas y a la vez cumplir los estándares internacionales. El estudio tiene por objeto la dirección integral de proyectos de las empresas operadoras de petróleo y gas en el país tomando como caso de estudio a la empresa petrolera YPFB Chaco S.A. Teniendo como campo de acción: la Economía boliviana, los recursos humanos, las operaciones de YPFB y la Dirección de proyectos hidrocarburíferos. El proyecto se plantea en virtud de la coyuntura estacional que viven el país con una disminución de la producción de gas y la tendencia a reducir las reservas en el Estado Plurinacional de Bolivia

Unidades de endulzamiento por aminas de planta de gas

An alternative fuel that has emerged today is natural gas. Natural gas is a mixture of gaseous hydrocarbons formed mainly by methane. However, because it is found in natural underground deposits, it is accompanied by various impurities or contaminants, among which are the acid gases H2S and CO2 that cause corrosion in the lines and process equipment, making its distribution difficult, reducing its energy power and increasing toxicity in the gases emitted during combustion. For the removal or elimination of these acid compounds from the gas, absorption-desorption systems using a selective solvent are used. The fed gas is called "bitter", the product "sweet gas", and the process is generally known as "sweetening". There are several patents to carry out the natural gas sweetening process, which differ in the type and composition of the solvent used. The increase in the demand for natural gas makes it necessary to improve the sweetening process, by increasing the production of sweet gas and reducing operating costs. Studies carried out in this area are aimed at reducing amine losses, through the manipulation of operating variables and the implementation of devices, obtaining excellent results in cost savings without altering the capacity or quality of sweetening. As already proven, amine blends are the best method to increase capacity or improve efficiency in sweetening units. Currently the focus is directed towards secondary and tertiary amines, particularly on the use of mixtures of diethanolamine (DEA) and methyldiethanolamine (MDEA) to carry out CO2 separation. You can work with any mixture of amines in aqueous solution or you can add a physical solvent to it for study.Un combustible alterno que ha surgido actualmente es el gas natural. El gas natural es una mezcla de hidrocarburos gaseosos formado principalmente por metano. Sin embargo, debido a que se encuentra en depósitos naturales subterráneos viene acompañado de diversas impurezas o contaminantes, entre los cuales están los gases ácidos H2S y CO2 que provocan corrosión en las líneas y equipos de proceso dificultando su distribución, disminuyen su poder energético e incrementan la toxicidad en los gases emitidos durante la combustión. Para la remoción o eliminación de estos compuestos ácidos del gas se utilizan sistemas de absorción – desorción utilizando un solvente selectivo. El gas alimentado se denomina “amargo”, el producto “gas dulce” y el proceso se conoce generalmente como “endulzamiento”. Existen diversas patentes para llevar a cabo el proceso de endulzamiento del gas natural, las cuales difieren en el tipo y composición del solvente empleado. El aumento en la demanda de gas natural obliga a mejorar el proceso de endulzamiento, al incrementar la producción de gas dulce y disminuir los costos de operación. Estudios realizados en esta área se encaminan a la reducción de pérdidas de amina, mediante la manipulación de las variables operativas e implementación de dispositivos, obteniéndose excelentes resultados en el ahorro de costos sin alterar la capacidad ni la calidad de endulzamiento. Como ya se tiene comprobado, las mezclas de aminas son el mejor método para incrementar la capacidad o mejorar la eficiencia en las unidades de endulzamiento. Actualmente, el enfoque está dirigido hacia las aminas secundarias y terciarias, particularmente sobre el uso de mezclas de dietanolamina (DEA) y metildietanolamina (MDEA) para llevar a cabo la separación del CO2. Se puede trabajar con cualquier mezcla de aminas en solución acuosa o se le puede añadir a ésta un solvente físico para su estudio

The landscape of somatic copy-number alteration across human cancers

available in PMC 2010 August 18.A powerful way to discover key genes with causal roles in oncogenesis is to identify genomic regions that undergo frequent alteration in human cancers. Here we present high-resolution analyses of somatic copy-number alterations (SCNAs) from 3,131 cancer specimens, belonging largely to 26 histological types. We identify 158 regions of focal SCNA that are altered at significant frequency across several cancer types, of which 122 cannot be explained by the presence of a known cancer target gene located within these regions. Several gene families are enriched among these regions of focal SCNA, including the BCL2 family of apoptosis regulators and the NF-κΒ pathway. We show that cancer cells containing amplifications surrounding the MCL1 and BCL2L1 anti-apoptotic genes depend on the expression of these genes for survival. Finally, we demonstrate that a large majority of SCNAs identified in individual cancer types are present in several cancer types.National Institutes of Health (U.S.) (Dana-Farber/Harvard Cancer Center and Pacific Northwest Prostate Cancer SPOREs, P50CA90578)National Institutes of Health (U.S.) (Dana-Farber/Harvard Cancer Center and Pacific Northwest Prostate Cancer SPOREs, R01CA109038))National Institutes of Health (U.S.) (Dana-Farber/Harvard Cancer Center and Pacific Northwest Prostate Cancer SPOREs, R01CA109467)National Institutes of Health (U.S.) (Dana-Farber/Harvard Cancer Center and Pacific Northwest Prostate Cancer SPOREs, P01CA085859)National Institutes of Health (U.S.) (Dana-Farber/Harvard Cancer Center and Pacific Northwest Prostate Cancer SPOREs, P01CA 098101)National Institutes of Health (U.S.) (Dana-Farber/Harvard Cancer Center and Pacific Northwest Prostate Cancer SPOREs, K08CA122833

The EBM-DPSER conceptual model: integrating ecosystem services into the DPSIR framework

There is a pressing need to integrate biophysical and human dimensions science to better inform holistic ecosystem management supporting the transition from single species or single-sector management to multi-sector ecosystem-based management. Ecosystem-based management should focus upon ecosystem services, since they reflect societal goals, values, desires, and benefits. The inclusion of ecosystem services into holistic management strategies improves management by better capturing the diversity of positive and negative human-natural interactions and making explicit the benefits to society. To facilitate this inclusion, we propose a conceptual model that merges the broadly applied Driver, Pressure, State, Impact, and Response (DPSIR) conceptual model with ecosystem services yielding a Driver, Pressure, State, Ecosystem service, and Response (EBM-DPSER) conceptual model. The impact module in traditional DPSIR models focuses attention upon negative anthropomorphic impacts on the ecosystem; by replacing impacts with ecosystem services the EBM-DPSER model incorporates not only negative, but also positive changes in the ecosystem. Responses occur as a result of changes in ecosystem services and include inter alia management actions directed at proactively altering human population or individual behavior and infrastructure to meet societal goals. The EBM-DPSER conceptual model was applied to the Florida Keys and Dry Tortugas marine ecosystem as a case study to illustrate how it can inform management decisions. This case study captures our system-level understanding and results in a more holistic representation of ecosystem and human society interactions, thus improving our ability to identify trade-offs. The EBM-DPSER model should be a useful operational tool for implementing EBM, in that it fully integrates our knowledge of all ecosystem components while focusing management attention upon those aspects of the ecosystem most important to human society and does so within a framework already familiar to resource managers

Colliding Worlds: Asteroid research and the legitimization of war in space

Accepted versio

Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Dimethyl fumarate (DMF) inhibits inflammasome-mediated inflammation and has been proposed as a treatment for patients hospitalised with COVID-19. This randomised, controlled, open-label platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing multiple treatments in patients hospitalised for COVID-19 (NCT04381936, ISRCTN50189673). In this assessment of DMF performed at 27 UK hospitals, adults were randomly allocated (1:1) to either usual standard of care alone or usual standard of care plus DMF. The primary outcome was clinical status on day 5 measured on a seven-point ordinal scale. Secondary outcomes were time to sustained improvement in clinical status, time to discharge, day 5 peripheral blood oxygenation, day 5 C-reactive protein, and improvement in day 10 clinical status. Between 2 March 2021 and 18 November 2021, 713 patients were enroled in the DMF evaluation, of whom 356 were randomly allocated to receive usual care plus DMF, and 357 to usual care alone. 95% of patients received corticosteroids as part of routine care. There was no evidence of a beneficial effect of DMF on clinical status at day 5 (common odds ratio of unfavourable outcome 1.12; 95% CI 0.86-1.47; p = 0.40). There was no significant effect of DMF on any secondary outcome

Effect of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker initiation on organ support-free days in patients hospitalized with COVID-19

IMPORTANCE Overactivation of the renin-angiotensin system (RAS) may contribute to poor clinical outcomes in patients with COVID-19. Objective To determine whether angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) initiation improves outcomes in patients hospitalized for COVID-19. DESIGN, SETTING, AND PARTICIPANTS In an ongoing, adaptive platform randomized clinical trial, 721 critically ill and 58 non–critically ill hospitalized adults were randomized to receive an RAS inhibitor or control between March 16, 2021, and February 25, 2022, at 69 sites in 7 countries (final follow-up on June 1, 2022). INTERVENTIONS Patients were randomized to receive open-label initiation of an ACE inhibitor (n = 257), ARB (n = 248), ARB in combination with DMX-200 (a chemokine receptor-2 inhibitor; n = 10), or no RAS inhibitor (control; n = 264) for up to 10 days. MAIN OUTCOMES AND MEASURES The primary outcome was organ support–free days, a composite of hospital survival and days alive without cardiovascular or respiratory organ support through 21 days. The primary analysis was a bayesian cumulative logistic model. Odds ratios (ORs) greater than 1 represent improved outcomes. RESULTS On February 25, 2022, enrollment was discontinued due to safety concerns. Among 679 critically ill patients with available primary outcome data, the median age was 56 years and 239 participants (35.2%) were women. Median (IQR) organ support–free days among critically ill patients was 10 (–1 to 16) in the ACE inhibitor group (n = 231), 8 (–1 to 17) in the ARB group (n = 217), and 12 (0 to 17) in the control group (n = 231) (median adjusted odds ratios of 0.77 [95% bayesian credible interval, 0.58-1.06] for improvement for ACE inhibitor and 0.76 [95% credible interval, 0.56-1.05] for ARB compared with control). The posterior probabilities that ACE inhibitors and ARBs worsened organ support–free days compared with control were 94.9% and 95.4%, respectively. Hospital survival occurred in 166 of 231 critically ill participants (71.9%) in the ACE inhibitor group, 152 of 217 (70.0%) in the ARB group, and 182 of 231 (78.8%) in the control group (posterior probabilities that ACE inhibitor and ARB worsened hospital survival compared with control were 95.3% and 98.1%, respectively). CONCLUSIONS AND RELEVANCE In this trial, among critically ill adults with COVID-19, initiation of an ACE inhibitor or ARB did not improve, and likely worsened, clinical outcomes. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT0273570

Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Dimethyl fumarate (DMF) inhibits inflammasome-mediated inflammation and has been proposed as a treatment for patients hospitalised with COVID-19. This randomised, controlled, open-label platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing multiple treatments in patients hospitalised for COVID-19 (NCT04381936, ISRCTN50189673). In this assessment of DMF performed at 27 UK hospitals, adults were randomly allocated (1:1) to either usual standard of care alone or usual standard of care plus DMF. The primary outcome was clinical status on day 5 measured on a seven-point ordinal scale. Secondary outcomes were time to sustained improvement in clinical status, time to discharge, day 5 peripheral blood oxygenation, day 5 C-reactive protein, and improvement in day 10 clinical status. Between 2 March 2021 and 18 November 2021, 713 patients were enroled in the DMF evaluation, of whom 356 were randomly allocated to receive usual care plus DMF, and 357 to usual care alone. 95% of patients received corticosteroids as part of routine care. There was no evidence of a beneficial effect of DMF on clinical status at day 5 (common odds ratio of unfavourable outcome 1.12; 95% CI 0.86-1.47; p = 0.40). There was no significant effect of DMF on any secondary outcome